{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T16:41:52Z","timestamp":1788367312427,"version":"build-2803163510"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T00:00:00Z","timestamp":1561075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2019.00543","type":"journal-article","created":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T12:45:03Z","timestamp":1561121103000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":53,"title":["A Review of Ongoing Trials of Stereotactic Ablative Radiotherapy for Oligometastatic Cancers: Where Will the Evidence Lead?"],"prefix":"10.3389","volume":"9","author":[{"given":"Faiez","family":"Al-Shafa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Arifin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George B.","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander V.","family":"Louie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,6,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s13014-014-0230-6","article-title":"Oligometastasis and oligo-recurrence: more than a mirage","volume":"9","author":"Huang","year":"2014","journal-title":"Radiat Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-15-0822","article-title":"New strategies in stereotactic radiotherapy for oligometastases","volume":"21","author":"Palma","year":"2015","journal-title":"Clin Cancer Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/jjco\/hyp167","article-title":"Oligometastases and oligo-recurrence: the new era of cancer therapy","volume":"40","author":"Niibe","year":"2010","journal-title":"Jpn J Clin Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/PPO.0000000000000202","article-title":"Stereotactic body radiotherapy for oligometastasis opportunities for biology to guide clinical management","volume":"22","author":"Correa","year":"2016","journal-title":"Cancer J"},{"key":"B5","doi-asserted-by":"publisher","first-page":"8491","DOI":"10.18632\/oncotarget.3455","article-title":"The biology and treatment of oligometastatic cancer","volume":"6","author":"Reyes","year":"2015","journal-title":"Oncotarget"},{"key":"B6","doi-asserted-by":"publisher","first-page":"94","DOI":"10.21037\/atm.2018.01.19","article-title":"Surgical approach in the oligometastatic patient","volume":"6","author":"Crisci","year":"2018","journal-title":"Ann Transl Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0022-5223(97)70397-0","article-title":"Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases","volume":"113","author":"Pastorino","year":"1997","journal-title":"J Thorac Cardiovasc Surg."},{"key":"B8","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1097\/00000658-200206000-00002","article-title":"Trends in long-term survival following liver resection for hepatic colorectal metastases","volume":"235","author":"Choti","year":"2002","journal-title":"Ann Surg."},{"key":"B9","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1111\/j.1445-2197.2005.03585.x","article-title":"Complete resection of non-small-cell lung cancer and oligo-metastatic brain disease","volume":"75","author":"Daniels","year":"2005","journal-title":"ANZ J Surg."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1200\/JCO.2007.14.2091","article-title":"Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis","volume":"26","author":"Tanvetyanon","year":"2008","journal-title":"J Clin Oncol."},{"key":"B11","unstructured":"Central Nervous System Cancers (Version 2.2018)2018"},{"key":"B12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ijrobp.2007.12.031","article-title":"Long-term survival in patients with synchronous, solitary brain metastasis from non-small-cell lung cancer treated with radiosurgery","volume":"72","author":"Flannery","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"B13","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.lungcan.2013.07.026","article-title":"Is there an oligometastatic state in non-small cell lung cancer?","volume":"82","author":"Ashworth","year":"2013","journal-title":"Lung Cancer."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","article-title":"Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study","volume":"17","author":"Gomez","year":"2016","journal-title":"Lancet Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e173501","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1097\/COC.0000000000000169","article-title":"Definitive stereotactic body radiotherapy (SBRT) for extracranial oligometastases: an international survey of >1000 radiation oncologists","volume":"40","author":"Lewis","year":"2017","journal-title":"Am J Clin Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1177\/0300891618766820","article-title":"Stereotactic body radiotherapy for lung oligometastases: literature review according to PICO criteria","volume":"104","author":"Alongi","year":"2018","journal-title":"Tumori"},{"key":"B20","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.radonc.2019.01.001","article-title":"The METABANK score: a clinical tool to predict survival after stereotactic radiotherapy for oligometastatic disease","volume":"133","author":"Van","year":"2019","journal-title":"Radiother Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e0195149","DOI":"10.1371\/journal.pone.0195149","article-title":"Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: a multi-institutional pooled analysis","volume":"13","author":"Hong","year":"2018","journal-title":"PLoS ONE"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1002\/cncr.30058","article-title":"Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT)","volume":"122","author":"Wong","year":"2016","journal-title":"Cancer."},{"key":"B23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s12609-017-0234-y","article-title":"The abscopal effect of radiation therapy: what is it and how can we use it in breast cancer?","volume":"9","author":"Hu","year":"2017","journal-title":"Curr Breast Cancer Rep."},{"key":"B24","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","article-title":"Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial","volume":"18","author":"Shaverdian","year":"2017","journal-title":"Lancet Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1200\/JCO.2017.76.2229","article-title":"Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors","volume":"36","author":"Luke","year":"2018","journal-title":"J Clin Oncol."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.9023","article-title":"Randomized phase II study of pembrolizumab after stereotactic body radiotherapy (SBRT) versus pembrolizumab alone in patients with advanced non-small cell lung cancer: the PEMBRO-RT study","volume":"36","author":"Theelen","year":"2018","journal-title":"J Clin Oncol."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15","article-title":"A phase II randomized trial of nivolumab with stereotactic body radiotherapy (SBRT) versus nivolumab alone in metastatic (M1) head and neck squamous cell carcinoma (HNSCC)","volume":"36","author":"McBride","year":"2018","journal-title":"J Clin Oncol."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00543\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T12:45:06Z","timestamp":1561121106000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00543\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,21]]},"references-count":27,"alternative-id":["10.3389\/fonc.2019.00543"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2019.00543","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,21]]},"article-number":"543"}}